Table 1.
Parameter | Intravenous, 3 mg/kg (n = 8) |
Oral, fed 6 mg/kg (n = 11) b |
Oral, fasted 6 mg/kg (n = 6) |
---|---|---|---|
Actual doses (mg/kg) | 3.07 ± 0.07 | 7.52 ± 0.83 | 8.00 ± 0.70 |
Tmax (hours) | na | 4 (range: 1–24) | 2 (range: 1–4) |
Cmax (ng/ml) | na | 3004 ± 709 | 348 ± 249 |
AUClast (day*ng/ml) | 13,238 ± 2839 | 33,907 ± 6611 | 2901 ± 2207 |
AUCinf (day*ng/ml) | 23,776 ± 9131 | 68,418 ± 23,220 | 4876 ± 3610 |
Cmax (dose normalized) (ng/ml)a | na | 403.4 ± 107.0 | 43.6 ± 28.6 |
AUClast (dose normalized) (day*ng/ml)a | 4315 ± 862 | 4554 ± 762 | 364 ± 255 |
AUCinf (dose normalized) (day*ng/ml)a | 7750 ± 2876 | 9188 ± 3632 | 612 ± 420 |
T1/2z (day) | 28.6 ± 14.3 | 33.6 ± 22.0 | 27.1 ± 7.7 |
MRT (day) | 41.6 ± 19.5 | 48.9 ± 30.7 | 38.6 ± 9.9 |
CL (l/kg/day) | 0.13 ± 0.05 | na | na |
Vz (l/kg) | 5.34 ± 1.49 | na | na |
Vss (l/kg) | 5.37 ± 1.37 | na | na |
Bioavailability (F%) | na | 106 | 8.4 |
aDose-normalized to 1 mg/kg
aOne cat had an adverse event unrelated to the treatment (leg fracture) and was withdrawn from the study